- Home
- GILD vs MRK Comparison
GILD vs MRK Comparison
Compare GILD & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | MRK |
|---|---|---|
| Founded | 1987 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4B | 268.7B |
| IPO Year | 2000 | 1994 |
Fundamental Metrics
Financial Performance| Metric | GILD | MRK |
|---|---|---|
| Price | $145.35 | $116.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 14 |
| Target Price | ★ $146.50 | $123.21 |
| AVG Volume (30 Days) | 5.7M | ★ 8.2M |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | 2.25% | ★ 2.93% |
| EPS Growth | ★ 1684.21 | 8.01 |
| EPS | 6.78 | ★ 7.28 |
| Revenue | $24,689,000,000.00 | ★ $65,011,000,000.00 |
| Revenue This Year | $4.68 | $3.74 |
| Revenue Next Year | $6.10 | $5.47 |
| P/E Ratio | $21.53 | ★ $15.96 |
| Revenue Growth | ★ 9.98 | 1.31 |
| 52 Week Low | $95.30 | $75.40 |
| 52 Week High | $157.29 | $125.14 |
Technical Indicators
Market Signals| Indicator | GILD | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 50.93 | 46.59 |
| Support Level | $143.09 | $105.23 |
| Resistance Level | $157.29 | $125.14 |
| Average True Range (ATR) | 3.22 | 2.83 |
| MACD | -1.01 | -1.07 |
| Stochastic Oscillator | 36.53 | 22.00 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).